Patent application number | Description | Published |
20090023738 | DIAMINOPYRIMIDINES AS MODULATORS OF THE EP2 RECEPTOR - The present invention relates to diaminopyrimidines of the general formula I, process for their preparation, and the use thereof for the manufacture of pharmaceutical compositions for the treatment of disorders and indications connected with the EP | 01-22-2009 |
20090023741 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR - The present invention relates to aryl/hetarylamide derivatives of the general formula I, process for their preparation, and the use thereof for the manufacture of pharmaceutical compositions for the treatment of disorders and indications connected with the EP | 01-22-2009 |
20090030010 | 3-Amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents - This invention relates to compounds of general formula I | 01-29-2009 |
20090042878 | THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR - The present invention relates to thienopyrimidylamines of the general formula I, to processes for their preparation and to their use for production of pharmaceutical compositions for treatment of disorders and indications connected to the EP | 02-12-2009 |
20090042882 | SUBSTITUTED ACETAMIDES AS MODULATORS OF THE EP2 RECEPTOR - The present invention relates to substituted acetamides of the general formula I, process for their preparation, and the use thereof for the manufacture of pharmaceutical compositions for the treatment of disorders and indications connected with the EP | 02-12-2009 |
20090042913 | Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor - The present invention relates to indolylalkylthienopyrimidylamines of the general formula I, to processes for their preparation and to their use for production of pharmaceutical compositions for treatment of disorders and indications connected to the EP | 02-12-2009 |
20100029598 | Extended Benzamide Derivatives as Modulators of the EP2 Receptor - The present invention relates to extended benzamide derivatives of the general formula I, to processes for preparation thereof and to use thereof for production of pharmaceutical compositions for treatment of disorders and indications associated with the EP | 02-04-2010 |
20100029599 | Indolylamides as modulators of the EP2 receptor - The present invention relates to indolylamide derivatives of the general formula (I), to processes for preparation thereof and to use thereof for production of pharmaceutical compositions for treatment of disorders and indications associated with the EP | 02-04-2010 |
20130252890 | 6,7-DIHYDRO-5H-BENZO[7]ANNULENE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, PHARMACEUTICAL PREPARATIONS COMPRISING THEM, AND THE USE THEREOF FOR PRODUCTION OF MEDICAMENTS - The invention relates to selective oestrogen receptor modulators (SERM) and methods of production thereof, use thereof for the treatment and/or prophylaxis of diseases and use thereof for the production of medicinal products for the treatment and/or prophylaxis of diseases, in particular of bleeding disorders, osteoporosis, endometriosis, myomata, hormone-dependent tumours, for hormone replacement therapy and for contraception. | 09-26-2013 |
20140336172 | Novel 2H-Indazoles as EP2 Receptor Antagonists - The present invention relates to novel 2H-indazoles of the general formula (I), methods for the preparation thereof and the use thereof for the production of pharmaceutical agents for the treatment of diseases and indications which are linked with the EP | 11-13-2014 |
20150080438 | 6,7-Dihydro-5H-benzo[7]annulene derivatives, processes for their preparation, pharmaceutical products comprising them and their use for preparing medicaments - The invention relates to selective oestrogen receptor modulators (SERMs) and to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of bleeding disorders, osteoporosis, endometriosis, myomata, hormone-dependent tumours, for hormone replacement therapy and for contraception. | 03-19-2015 |